Brookline Capital Markets Weighs in on SABS FY2030 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at Brookline Capital Markets upped their FY2030 earnings estimates for SAB Biotherapeutics in a report released on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn $1.38 per share for the year, up from their prior estimate of $1.17. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.19) per share.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28).

SABS has been the topic of a number of other reports. Rodman & Renshaw restated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a report on Monday, June 15th. Wall Street Zen cut SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, August 2nd. Jefferies Financial Group started coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Trading Up 2.1%

Shares of SAB Biotherapeutics stock opened at $3.85 on Friday. The firm has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $3.83. The company has a market cap of $294.37 million, a P/E ratio of -1.82 and a beta of 0.53. SAB Biotherapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently modified their holdings of the stock. Vivo Capital LLC purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $22,954,000. Perceptive Advisors LLC raised its position in shares of SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after purchasing an additional 5,628,533 shares during the last quarter. RA Capital Management L.P. purchased a new position in SAB Biotherapeutics in the 3rd quarter valued at about $8,847,000. Woodline Partners LP purchased a new position in SAB Biotherapeutics in the 3rd quarter valued at about $5,730,000. Finally, Spruce Street Capital LP acquired a new stake in SAB Biotherapeutics in the 4th quarter worth about $8,222,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.